RxDoctor Payments Data

Sametta Sanyaolu

Family · Fulton, MDNPI 1730695503

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 2,060 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,370in general payments, 2019–2025

Across 2,060 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Biogen$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Pfizer$2K
  • Amgen$1K
  • ANI Pharmaceuticals, Inc.$1K
  • plus $19K from 54 others

What the payments were for

  • Consulting fees$3001%
  • Food & beverage$36,45798%
  • Education$6132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)635$7,695
Biogen154$3,118
Teva Pharmaceuticals USA, Inc.70$2,599
Pfizer100$1,769
Amgen(2 entities)62$1,395
ANI Pharmaceuticals, Inc.66$1,314
Lundbeck LLC71$1,265
UCB, Inc.60$1,194
Amneal Pharmaceuticals LLC34$1,029
Argenx US, Inc.44$1,006
Neurocrine Biosciences, Inc.30$954
Bristol Myers Squibb47$907
Biohaven Pharmaceutical Holding Company Ltd.53$870
Neurelis, Inc.39$845
Eisai Inc.36$771
Johnson & Johnson67$761
Lilly USA, LLC28$690
Axsome Therapeutics, Inc.30$662
Kyowa Kirin, Inc.31$650
Genentech USA, Inc.23$574
Currax Pharmaceuticals LLC56$521
CSL Behring19$507
Vanda Pharmaceuticals Inc.19$496
Sunovion Pharmaceuticals Inc.29$462
AstraZeneca16$427
TG Therapeutics, Inc.21$421
Scilex Pharmaceuticals Inc.17$361
Sumitomo Pharma America, Inc.22$343
Catalyst Pharmaceuticals, Inc.16$294
MDD US Operations, LLC3$293
Mallinckrodt Hospital Products Inc.15$283
Collegium Pharmaceutical, Inc.15$231
Alnylam Pharmaceuticals Inc.9$228
Biohaven Pharmaceuticals, Inc.14$208
Takeda Pharmaceuticals U.S.A., Inc.8$197
Avion Pharmaceuticals14$170
Avanir Pharmaceuticals, Inc.9$164
Grifols USA, LLC8$164
Acorda Therapeutics, Inc8$161
Impel Pharmaceuticals Inc.7$143
Sanofi5$124
Azurity Pharmaceuticals, Inc.5$112
Supernus Pharmaceuticals, Inc.4$96
Otsuka America Pharmaceutical, Inc.4$86
Upsher-smith Laboratories LLC4$70
Livanova USA, Inc.3$68
Springworks Therapeutics, Inc.3$68
Sandoz2$54
Banner Life Sciences, LLC3$54
Jazz Pharmaceuticals Inc.2$51
Impel Pharmaceuticals LLC2$45
Almatica Pharma LLC2$44
Tanabe Pharma America, Inc.2$43
Adamas Pharmaceuticals, Inc.2$40
Novocure Inc.1$38
Merck2$36
Insightec,inc1$32
SK Life Science, Inc.1$30
Abbott1$26
Octapharma USA, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,370 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$66,406
Medicare patients
259
Services billed
1,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant32$49,973
Nurtec OdtRimegepant Sulfate18$48,144
QuliptaAtogepant23$38,760
VimpatLacosamide14$35,263
BotoxOnabotulinumtoxina26$33,440
BriviactBrivaracetam17$24,059
HorizantGabapentin Enacarbil11$20,762
Ajovy AutoinjectorFremanezumab-Vfrm12$15,429
NamzaricMemantine Hcl/Donepezil Hcl11$6,731
Rivastigmine38$5,856
Lacosamide18$4,585
Memantine Hcl113$3,609
Gabapentin104$2,195
Levetiracetam36$2,191
Sumatriptan Succinate13$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox, Namzaric$7,695$128,90492 claims
UCB, Inc.Vimpat, Briviact$1,194$59,32231 claims
PfizerNurtec Odt$1,769$48,14418 claims
Upsher-smith Laboratories LLCTopiramate$70$37934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Fulton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →